These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar

Zacks identifies Pfizer and Johnson & Johnson as potential earnings beat candidates ahead of their upcoming reports. Pfizer's Most Accurate Estimate is $0.84 per share versus a $0.75 consensus, for a +12.30% Earnings ESP; Johnson & Johnson's is $2.71 versus $2.66, for +2.10%. The article cites historical Zacks data showing that stocks with a Zacks Rank of #3 or better and positive ESP beat estimates 70% of the time, but neither company has reported results yet.

Analysis

Treat the estimate-revision signal as an event-risk screen, not evidence of improving underlying economics. A reported EPS beat can be low quality if driven by tax, costs, or timing; the market is more likely to reward corroboration from revenue trends, product mix, and forward guidance. The larger revision gap at Pfizer gives it the stronger statistical setup, but also leaves more room for a crowded, already-priced trade. Johnson & Johnson’s narrower gap is especially vulnerable to an in-line result being treated as a miss. In the next few days, J&J’s report is the immediate catalyst; Pfizer’s later report offers time for estimates and positioning to change. Over 1–3 months, guidance and subsequent estimate revisions matter more than the headline beat. Over 6–18 months, durable performance depends on product and segment growth offsetting patent, litigation, and execution risks—not on this screen. The cited backtest is not a forecast: methodology, transaction costs, selection effects, and performance across different market regimes are not established here. There is no clear read-through to peers or suppliers absent evidence of a sector-wide estimate trend. The contrarian risk is that investors trade the probability of a beat while overlooking whether expectations for the following quarters are being raised. Falsify a bullish read if either company beats EPS but cuts or fails to support its outlook, or if post-report analyst revisions turn negative.

Key Decisions for Investors

• Do not buy either name solely on the ESP signal. For J&J, stay event-neutral into the imminent report; reassess after results, prioritizing segment sales and forward outlook over adjusted EPS.
• For Pfizer, place on a post-earnings watchlist rather than pre-positioning: consider a modest long only if a beat is accompanied by supportive revenue and guidance and analysts subsequently revise estimates upward. Exit the thesis on a guidance cut or negative follow-on revisions.
• Do not force a JNJ/PFE pair trade from these signals alone: the revision gap does not establish relative fundamentals, valuation, or a durable spread catalyst.
• Before any event options trade, compare implied move and premium with each stock’s historical earnings moves; those data are absent here. Avoid paying for a beat if the expected move already discounts it.